(Q49132862)

English

Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice.

scientific article published on 3 August 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

1 reference

based on heuristic

inferred from title

author name string

Qiu Xia

1

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Fei Geng

2

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Fang-Fang Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Chen-Lu Liu

4

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Ping Xu

5

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Zhen-Zhen Lu

6

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Hai-Hong Zhang

7

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Wei Kong

8

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Xiang-Hui Yu

9

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

language of work or name

0 references

publication date

3 August 2016

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

34

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

38

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

4526-4535

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Cancer-associated fibroblasts and tumor growth--bystanders turning into key players

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Fibroblasts in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

The role of microenvironment in tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Molecular cloning of seprase: a serine integral membrane protease from human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Fibroblast activation protein: A potential therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

DNA vaccination against tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Novel adenovirus vector-based vaccines for HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Current status of interleukin-10 and regulatory T-cells in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

T cell exclusion, immune privilege, and the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Cancer prevention and therapy through the modulation of the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Imaging the Tumor Microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.07.054

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.07.054

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 February 2018

http://europepmc.org/abstract/MED/27498213

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49132862&oldid=1715365973"